Influence of Fluvoxamine on the Pharmacokinetics of BI 409306 After Oral Administration (Randomized, Open-label, Two-treatment, Two-sequence, Two-period Crossover Study)
Phase of Trial: Phase I
Latest Information Update: 21 Jun 2017
At a glance
- Drugs BI 409306 (Primary) ; Fluvoxamine (Primary)
- Indications Alzheimer's disease; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 10 Jan 2017 Status changed from recruiting to completed.
- 01 Sep 2016 Status changed from not yet recruiting to recruiting.
- 04 Aug 2016 New trial record